Kolexia
Bijou Fontanet Hématologie
Bijou Fontanet
Hématologie
Institut Bergonié
Bordeaux, France
112 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Lymphomes Lymphome B Maladie de Hodgkin Lymphome folliculaire Lymphome malin non hodgkinien Lymphome B diffus à grandes cellules Leucémies Récidive tumorale locale Neutropénie

Collaborateurs

Voir plus
Morschhauser Franck
Morschhauser Franck
Centre Hospitalier de Lille, Lille, France
Haioun Corinne
Haioun Corinne
Hôpital Henri Mondor, Créteil, France
Salles Gilles
Salles Gilles
Hôpital Lyon Sud, Pierre-Bénite, France
Houot Roch
Houot Roch
Hôpital Pontchaillou, Rennes, France

Industries

Voir plus
BEIGENE
34 collaboration(s)
Dernière en 2023
Abbvie
8 collaboration(s)
Dernière en 2023
Celgene
2 collaboration(s)
Dernière en 2020
Janssen
2 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
MorningLyte: A Phase III Randomized, Open-label, International, Multicenter Study Evaluating the Efficacy and Safety of Mosunetuzumab Plus Lenalidomide in Comparison to Anti-CD20 Monoclonal Antibody Plus Chemotherapy in Subjects With Previously Untreated FLIPI 2-5 Follicular Lymphoma
Essai Clinique (The Lymphoma Academic Research Organisation)   13 mars 2024
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL): A Phase 1/2, Multi-center, Open-label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination With Anti-Lymphoma Agents in Subjects With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL).
Essai Clinique (Celgene)   04 mars 2024
BRUIN-MCL-321: A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Essai Clinique (Loxo Oncology, Inc.)   24 janvier 2024
Study of Lacutamab in Peripheral T-cell Lymphoma: A Randomized Non Comparative Phase II Study of Lacutamab With GemOx Versus GemOx Alone in Relapsed/Refractory Patients With Peripheral T-cell Lymphoma
Essai Clinique (Innate Pharma)   04 décembre 2023
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY.
EClinicalMedicine   15 novembre 2023
ROSEWOOD: An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma
Essai Clinique (BeiGene)   08 novembre 2023
Synthetic Control Arm from Clinical Trials and Real-World Data from Lysa Group for Untreated Diffuse Large B Cell Lymphoma Patients Aged over 80 Years: A Bona Fide Strategy for Innovative Clinical Trials
65th ASH Annual Meeting Abstracts   02 novembre 2023
Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort.
Blood advances   24 octobre 2023
Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group.
Blood advances   23 octobre 2023
A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.: A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 in Combination With Obinutuzumab (GA101) in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Indolent Non-Hodgkin's Lymphoma
Essai Clinique (Celgene)   19 octobre 2023